Publications

Primary health care (PHC) is the essential strategy for reorientating health systems and societies to become healthier, equitable, effective and sustainable. WHO outlines 14 strategic and operational levers for policy-makers to strengthen PHC. Within each lever, there are multiple potential entry points for targeted actions to address racial discrimination, foster intercultural care, and reduce health inequities experienced by indigenous peoples as well as people of African descent, Roma and other ethnic minorities.

Just as UNAIDS calls for ending inequalities to end AIDS, we are building an internal culture of equality through our Culture Transformation. This journey is grounded in intersectional feminist and anti-racist thinking and practice. It also provides reflective spaces, values introspection and offers opportunity to experiment with different ways of working and learning together.

The WHO Global Tuberculosis Report 2022 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets. The 2022 edition of the report is as usual, based primarily on data gathered by WHO from national ministries of health in annual rounds of data collection. In 2022, 202 countries and territories with more than 99% of the world’s population and TB cases reported data.

Mongolia has undertaken an assessment of spending on national HIV/AIDS response since 2012.The first National AIDS Spending Assessment (NASA) report focusing on expenditures in 2010-2011 was published and disseminated to decision-makers and relevant governmental and non governmental organizations (NGO) in 2012. The current report summarizes the findings of the third NASA. Unlike the previous two assessments conducted in 2012 and 2014, which estimated biennial expenditures, the current exercise assessed total spending on national HIV/AIDS response for a period of three years (2014, 2015 and 2016). 

Facilitating access to formulations of the HIV medicine dolutegravir (DTG) that can be used by infants and children living with HIV in the Asia-Pacific is an urgent concern. In light of recent U.S. and European regulatory approvals of a dispersible version of pediatric DTG, amfAR’s TREAT Asia program recommends steps that national HIV programs and advocacy groups can take in order to secure access to this medicine as quickly as possible.

The purpose of this paper is to contribute to the dialogue among communities, governments, development partners and international organisations in Asia and the Pacific on strategies and models for ensuring the sustainable participation of HIV key population communities and community organisations. It summarises information from a desk-review of formal and informal literature, and a set of targeted key informant interviews with relevant agencies in the Asia and the Pacific region.  

This report analyses the intersection of HIV, COVID-19 and public debt in developing countries. The collision between COVID-19 and a crippling debt crisis have reversed decades of progress - putting present and future investments in health and HIV at risk. Pragmatic options to address the pandemic triad are proposed.

The operational handbook provides laboratory personnel, clinicians as well as ministries of health and technical partners detailed guidance on how to implement the WHO evidence-based recommendations on TB infection tests. The document describes the WHO recommended tests, test procedures, a model algorithm, and the steps required to scale-up TB infection testing within a health programme.

The Framework for collaborative action on TB and comorbidities aims to support countries in the evidence-informed introduction and scale-up of holistic people-centred services for TB, comorbidities and health-related risk factors, with the goal of comprehensively addressing TB and other co-existing health conditions. It should be used in conjunction with relevant WHO guidelines. ties. The Framework is intended for use by people working in ministries of health, other relevant line-ministries, policymakers, international technical and funding organizations, researchers, nongovernmental and civil society organizations, as well as primary care workers, specialist health practitioners, and community health workers who support the response to TB and comorbidities in both the public and private sectors.

The Global Plan to End TB, 2023–2030 (Global Plan) is a plan for ending tuberculosis (TB) as a public health challenge by 2030—the year by which governments around the world have committed to achieving the United Nations (UN) Sustainable Development Goals. This document provides the most detailed costing estimates of any Global Plan to date and builds on the previous edition, Paradigm Shift, which laid out priority actions for 2018–2022 informed by global commitments endorsed by Member States at the 2018 UN High-Level Meeting (UNHLM) on TB. This Global Plan anticipates the priority actions that will be necessary in the wake of the COVID-19 pandemic and informs follow-up commitments to be made at a second UNHLM on TB in 2023.